Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation antigen (BCMA) receptor. It received accelerated approval in 2022 for patients treated with four or more lines of prior therapy based on results from the Phase I/II MajesTEC-1 clinical trial.
from Medical Xpress - latest medical and health news stories https://ift.tt/FQHWRiN
